FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 759 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... April 26, 2022 Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma September 8, 2023 Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy... January 14, 2025 A career forged in team science March 10, 2023 Load more HOT NEWS Study Says Educational Materials for Chemo Often Require Higher Reading Level... Dress up that Salad! For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily Scientists reveal how air pollution can cause lung cancer in people...
